Genomic Assays by Mutations

The KRAS gene encodes a GTPase that regulates cell proliferation, survival, and cytoskeletal organization. Oncogenic mutations in KRAS allow for persistent signaling and cancer development, particularly in colorectal cancers (CRC) and NSCLC.

For KRAS assessment, we offer:

• therascreen KRAS RGQ PCR kit (DNA from FFPE samples, mutations in codons 12 and 13)
• cobas(R) KRAS Mutation test (DNA from FFPE samples, mutations in codons 12,13, and 61)

For details on these assays, download our brochure.

The BRAF gene encodes a kinase that mediates the effects of growth factors like EGFR. Oncogenic mutations in BRAF lead to uncontrolled pathway activation, contributing to many cancers, including melanoma, CRC, ovarian cancer, and thyroid cancer.

For BRAF assessment, we offer:

• therascreen BRAF V600E RGQ PCR kit (DNA from FFPE CRC tumor tissues, V6000E mutations)
• cobas(R) BRAF Mutation test (DNA from FFPE samples, V600E mutations)

For details on these assays, download our brochure

The FGFR gene family encodes receptor tyrosine kinases that activate signaling pathways controlling cell growth, survival, and migration. Oncogenic alterations of FGFR contribute to tumor development in cancers such as urothelial carcinoma (UC).

For FGFR assessment, we offer:

• therascreen FGFR RGQ PCR kit (RNA from FFPE samples, point mutations in exon7, 10, and FGFR-TACC fusion)

For details on these assays, download our brochure

The PI3KCA gene encodes a catalytic subunit of the PI3K enzyme that regulates cell growth, survival, metabolism, and migration. Activating mutations in PI3KCA increases PI3K signaling, driving the development of cancer like hormone-positive breast cancer. CellCarta has options for both solid tumors and plasma samples.

For PI3KCA assessment, we offer:

• therascreen PIK3CA RGQ PCR kit (DNA from FFPE and plasma samples, mutations in exons 7, 9, 15, 20)

For details on these assays, download our brochure